452 related articles for article (PubMed ID: 33066042)
41. Signaling through the S1P-S1PR Axis in the Gut, the Immune and the Central Nervous System in Multiple Sclerosis: Implication for Pathogenesis and Treatment.
Chatzikonstantinou S; Poulidou V; Arnaoutoglou M; Kazis D; Heliopoulos I; Grigoriadis N; Boziki M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831439
[TBL] [Abstract][Full Text] [Related]
42. Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis.
Schepers M; Paes D; Tiane A; Rombaut B; Piccart E; van Veggel L; Gervois P; Wolfs E; Lambrichts I; Brullo C; Bruno O; Fedele E; Ricciarelli R; Ffrench-Constant C; Bechler ME; van Schaik P; Baron W; Lefevere E; Wasner K; Grünewald A; Verfaillie C; Baeten P; Broux B; Wieringa P; Hellings N; Prickaerts J; Vanmierlo T
Brain Behav Immun; 2023 Mar; 109():1-22. PubMed ID: 36584795
[TBL] [Abstract][Full Text] [Related]
43. GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis.
Qin J; Sikkema AH; van der Bij K; de Jonge JC; Klappe K; Nies V; Jonker JW; Kok JW; Hoekstra D; Baron W
J Neurosci; 2017 Oct; 37(41):9925-9938. PubMed ID: 28899916
[TBL] [Abstract][Full Text] [Related]
44. The complex world of oligodendroglial differentiation inhibitors.
Kremer D; Aktas O; Hartung HP; Küry P
Ann Neurol; 2011 Apr; 69(4):602-18. PubMed ID: 21520230
[TBL] [Abstract][Full Text] [Related]
45. Pericytes in Multiple Sclerosis.
Rivera FJ; Hinrichsen B; Silva ME
Adv Exp Med Biol; 2019; 1147():167-187. PubMed ID: 31147878
[TBL] [Abstract][Full Text] [Related]
46. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
[TBL] [Abstract][Full Text] [Related]
47. Mesenchymal stem cell conditioning promotes rat oligodendroglial cell maturation.
Jadasz JJ; Kremer D; Göttle P; Tzekova N; Domke J; Rivera FJ; Adjaye J; Hartung HP; Aigner L; Küry P
PLoS One; 2013; 8(8):e71814. PubMed ID: 23951248
[TBL] [Abstract][Full Text] [Related]
48. The Molecular Basis for Remyelination Failure in Multiple Sclerosis.
Gruchot J; Weyers V; Göttle P; Förster M; Hartung HP; Küry P; Kremer D
Cells; 2019 Aug; 8(8):. PubMed ID: 31382620
[TBL] [Abstract][Full Text] [Related]
49. Adenosine A
Coppi E; Cherchi F; Fusco I; Dettori I; Gaviano L; Magni G; Catarzi D; Colotta V; Varano F; Rossi F; Bernacchioni C; Donati C; Bruni P; Pedata F; Cencetti F; Pugliese AM
Biochem Pharmacol; 2020 Jul; 177():113956. PubMed ID: 32251679
[TBL] [Abstract][Full Text] [Related]
50. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
[TBL] [Abstract][Full Text] [Related]
51. Thyroid Hormone Potentially Benefits Multiple Sclerosis via Facilitating Remyelination.
Zhang M; Ma Z; Qin H; Yao Z
Mol Neurobiol; 2016 Sep; 53(7):4406-16. PubMed ID: 26243185
[TBL] [Abstract][Full Text] [Related]
52. Attempts to Overcome Remyelination Failure: Toward Opening New Therapeutic Avenues for Multiple Sclerosis.
Motavaf M; Sadeghizadeh M; Javan M
Cell Mol Neurobiol; 2017 Nov; 37(8):1335-1348. PubMed ID: 28224237
[TBL] [Abstract][Full Text] [Related]
53. Intracellular Protein Shuttling: A Mechanism Relevant for Myelin Repair in Multiple Sclerosis?
Göttle P; Küry P
Int J Mol Sci; 2015 Jul; 16(7):15057-85. PubMed ID: 26151843
[TBL] [Abstract][Full Text] [Related]
54. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.
Wang J; Goren I; Yang B; Lin S; Li J; Elias M; Fiocchi C; Rieder F
Aliment Pharmacol Ther; 2022 Feb; 55(3):277-291. PubMed ID: 34932238
[TBL] [Abstract][Full Text] [Related]
55. Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells.
Zveik O; Fainstein N; Rechtman A; Haham N; Ganz T; Lavon I; Brill L; Vaknin-Dembinsky A
Glia; 2022 Jun; 70(6):1191-1209. PubMed ID: 35266197
[TBL] [Abstract][Full Text] [Related]
56. Ponesimod for the treatment of relapsing multiple sclerosis.
Baldin E; Lugaresi A
Expert Opin Pharmacother; 2020 Nov; 21(16):1955-1964. PubMed ID: 32808832
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival.
Medina-Rodríguez EM; Arenzana FJ; Pastor J; Redondo M; Palomo V; García de Sola R; Gil C; Martínez A; Bribián A; de Castro F
Cell Mol Life Sci; 2013 Sep; 70(18):3449-62. PubMed ID: 23661015
[TBL] [Abstract][Full Text] [Related]
58. Activation of FXR pathway does not alter glial cell function.
Albrecht S; Fleck AK; Kirchberg I; Hucke S; Liebmann M; Klotz L; Kuhlmann T
J Neuroinflammation; 2017 Mar; 14(1):66. PubMed ID: 28351411
[TBL] [Abstract][Full Text] [Related]
59. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
Constantinescu V; Akgün K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):675-693. PubMed ID: 36260948
[TBL] [Abstract][Full Text] [Related]
60. Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation.
Miller LG; Young JA; Ray SK; Wang G; Purohit S; Banik NL; Dasgupta S
Neurochem Res; 2017 Oct; 42(10):2755-2768. PubMed ID: 28474276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
